Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.
Leuk Lymphoma. 2022 Aug;63(8):1871-1878. doi: 10.1080/10428194.2022.2095623. Epub 2022 Jul 18.
Leuk Lymphoma. 2022.
PMID: 35848865
Clinical Trial.
Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.
Sasse S, Alram M, Müller H, Smardová L, Metzner B, Doehner H, Fischer T, Niederwieser DW, Schmitz N, Schäfer-Eckart K, Raemaekers JM, Schmalz O, Tresckow BV, Engert A, Borchmann P.
Sasse S, et al. Among authors: tresckow bv.
Leuk Lymphoma. 2016 May;57(5):1067-73. doi: 10.3109/10428194.2015.1083561. Epub 2015 Dec 23.
Leuk Lymphoma. 2016.
PMID: 26693800
Clinical Trial.
Item in Clipboard
Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center.
Momotow J, Goergen H, Behringer K, Bröckelmann PJ, Borchmann S, Tresckow BV, Kobe C, Engert A, Sasse S.
Momotow J, et al. Among authors: tresckow bv.
Hemasphere. 2019 Sep 27;3(4):e293. doi: 10.1097/HS9.0000000000000293. eCollection 2019 Oct.
Hemasphere. 2019.
PMID: 31942546
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite